Ovid Q1 net loss $13.4M; cash $117.7M; adds ROCK2 program via Graviton

Ovid Therapeutics Inc.

2023-Q1 EPS reported -$0.19 revenue$222,600,000

Net loss $13.4M ($0.19 loss per share) vs $16.1M ($0.23) in Q1 2022; operating expenses $15.0M.
Cash, equivalents and marketable securities $117.7M as of March 31; expected runway into 2025.
Collaboration with Graviton adds GV101 (ROCK2 inhibitor); Phase 2 for brainstem cavernous malformations targeted for 2024.
OV329 Phase 1 on track with no safety signals; full data expected H1 2024; OV350 advancing preclinically.
Concluding Columbia University genetic collaboration by year-end; out-licensing options explored.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 5, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing First Quarter 2023 Financial Results and Corporate Updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.